IN8bio's Glioblastoma Trials Show Promising Results with DeltEx Drug-Resistant Immunotherapy

IN8bio's DeltEx Drug-Resistant Immunotherapy shows promising results in glioblastoma trials, with significant improvement in progression-free and overall survival rates compared to standard-of-care treatments. The therapy has a strong safety profile with no major adverse effects reported, paving the way for potential FDA consultations. The company's financial health is strong, with a current ratio of 6.91, debt-to-equity ratio of 0.22, and cash ratio of 6.28. However, profitability metrics are negative due to the lack of revenue.